Biogen (BIIB) is a publicly traded Healthcare sector company. As of November 18, 2026, BIIB trades at $247.50 with a market cap of $37.20B and a P/E ratio of 39.28. BIIB moved -0.33% today. Year to date, BIIB is +43.65%; over the trailing twelve months it is +52.33%. Its 52-week range spans $110.04 to $261.00. Analyst consensus is buy with an average price target of $267.04. Rallies surfaces BIIB's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
25 analysts cover BIIB: 0 strong buy, 18 buy, 6 hold, 1 sell, and 0 strong sell. The consensus rating is buy. The average price target is $267.04.
| Metric | Value |
|---|---|
| Price | $247.50 |
| Market Cap | $37.20B |
| P/E Ratio | 39.28 |
| EPS | $5.68 |
| Dividend Yield | 0.00% |
| 52-Week High | $261.00 |
| 52-Week Low | $110.04 |
| Volume | 681.27K |
| Avg Volume | 0 |
| Revenue (TTM) | $10.03B |
| Net Income | $834.60M |
| Gross Margin | 74.00% |
25 analysts cover BIIB: 0 strong buy, 18 buy, 6 hold, 1 sell, 0 strong sell. Consensus rating is buy. Average price target: $267.04.